Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Various

Therapeutic area intelligence for Various with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Companies: 2

Companies

Assets

Various Products →

Recent signals(5)

StrategyJuly 23, 2026

Roche Reports Strong H1 2026 Sales Growth and Multiple FDA Priority Reviews

Roche's pharmaceuticals division saw a 6% sales increase in H1 2026, driven by key products and multiple FDA Priority Reviews for new therapies.

StrategyJuly 23, 2026

Roche Reports Strong H1 2026 Sales and Multiple FDA Priority Reviews

Roche's H1 2026 sales increased by 6% at constant exchange rates, driven by strong demand for innovative medicines. The FDA granted Priority Reviews for five key therapies, including giredestrant for breast cancer and Enspryng for thyroid eye disease.

RegulatoryJuly 23, 2026

Roche Reports Strong H1 2026 Sales Growth and Multiple FDA Priority Reviews

Roche received five FDA Priority Reviews for key therapies including giredestrant for early-stage breast cancer and Enspryng for thyroid eye disease.

RegulatoryJuly 9, 2026

MHRA Launches Consultation for Earlier Licensing of Rare Disease Therapies

The MHRA has initiated a public consultation on a new framework aimed at expediting the licensing process for therapies targeting rare diseases.

RegulatoryJune 27, 2026

Bayer Plc Issues Class 3 Recall for Various Products Due to Impurity

Bayer Plc is recalling all stock of certain products due to an impurity identified above acceptable limits.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Rare Diseases →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.